Baxter International Inc (BAX) Stock Price & Analysis
Baxter International Inc (BAX) rose 3.37% to USD 22.4 as of July 25, 2026 at 01:44 UTC, according to Nexqual real-time market data.
BAX last closed at USD 21.67; the session ranged USD 21.92–22.64 on volume of 2,917,645 shares. Market capitalization is $11.57B, with a 52-week range of USD 15.73–29.35 (NYQ). Source: Nexqual, July 25, 2026 at 01:44 UTC.
Key Statistics (as of July 25, 2026 at 01:44 UTC)
| Price | USD 22.4 |
|---|---|
| Change | ▲ 3.37% (up) |
| Previous Close | USD 21.67 |
| Open | USD 21.95 |
| Day Range | USD 21.92 – 22.64 |
| 52-Week Range | USD 15.73 – 29.35 |
| Volume | 2,917,645 shares |
| Market Cap | $11.57B |
| Exchange | NYQ |
Technical Analysis (BAX)
Nexqual's technical model rates BAX "STRONG BUY" based on 5 bullish and 0 bearish signals across 125 daily candles, as of July 25, 2026 at 01:44 UTC.
| Overall Signal | STRONG BUY |
|---|---|
| RSI (14) | 56.58 (neutral) |
| vs SMA50 | Above (USD 20.5) |
| MACD | 0.45 (positive) |
Analyst Ratings (BAX)
Wall Street analysts rate BAX "Hold" based on 11 analysts, with a mean price target of USD 21.95 (range USD 17–40), per Nexqual as of July 25, 2026 at 01:44 UTC.
| Consensus Rating | Hold |
|---|---|
| Analyst Count | 11 |
| Mean Target | USD 21.95 |
| High Target | USD 40 |
| Low Target | USD 17 |
| Buy / Hold / Sell | 2 / 10 / 1 |
Earnings (BAX)
| Next Earnings Date | 2026-07-30 |
|---|---|
| EPS Estimate | USD 0.37 |
| Revenue Estimate | $2.79B |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD 0.36 vs est 0.31 ▲ beat |
| 2025-12-31 | USD 0.44 vs est 0.54 ▼ miss |
| 2025-09-30 | USD 0.69 vs est 0.6 ▲ beat |
| 2025-06-30 | USD 0.59 vs est 0.61 ▼ miss |
Source: Nexqual, July 25, 2026 at 01:44 UTC.
Financials & Fundamentals (BAX)
| Total Revenue | $11.32B |
|---|---|
| Revenue Growth (YoY) | +2.90% |
| Gross Margin | +34.65% |
| Operating Margin | +6.03% |
| Profit Margin | -9.70% |
| ROE | -15.01% |
| Debt / Equity | 161.02 |
| Current Ratio | 1.85 |
| Total Cash | $2.02B |
| Total Debt | $9.69B |
| Free Cash Flow | $900.88M |
Source: Nexqual, July 25, 2026 at 01:44 UTC.
Financial Health Score (BAX)
Nexqual rates Baxter International Inc's overall financial health "Mixed" across five dimensions, as of July 25, 2026 at 01:44 UTC.
| Growth | Solid — Revenue +6% YoY (annual) |
|---|---|
| Profitability | Solid — Gross margin 35%, operating 6% |
| Balance Sheet | Weak — $2.02B cash vs $9.69B debt |
| Cash Flow | Solid — FCF $901M, 8% margin |
| Efficiency | Critical — ROE -15%, ROA 2.8% |
Ownership (BAX)
| Insider Ownership | +0.34% |
|---|---|
| Institutional Ownership | +106.09% |
| Shares Outstanding | 516.47M |
| Float | 513.98M |
| Short % of Float | +11.80% |
Source: Nexqual, July 25, 2026 at 01:44 UTC.
Leadership (BAX)
Baxter International Inc is led by Andrew P. Hider (age 48), CEO, President, Interim Group President of Medical Products & Therapies and Director, per Nexqual as of July 25, 2026 at 01:44 UTC.
| CEO, President, Interim Group President of Medical Products & Therapies and Director | Andrew P. Hider (age 48) |
|---|---|
| Group President of Infusion Therapies & Platforms | Maria Soriano |
| Interim CFO, Senior VP, Chief Accounting Officer & Controller | Anita A. Zielinski (age 52) |
| Vice President & Head of Investor Relations | Kevin Moran |
| SVP, Chief Communications Officer & Corporate Marketing and President of Baxter Foundation | Stacey Eisen |
Major Backers & Investors (BAX)
Notable institutional backers of Baxter International Inc include Dodge & Cox Inc., Pzena Investment Management LLC, FMR, LLC, according to Nexqual as of July 25, 2026 at 01:44 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Dodge & Cox Inc. | 18.57% |
| Pzena Investment Management LLC | 12.49% |
| FMR, LLC | 8.96% |
| Invesco | 4.28% |
| Fidelity | 3.12% |
| Greenhaven Associates, Inc. | 2.77% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 22.62% |
| BlackRock | 19.22% |
| State Street | 3.87% |
| Geode Capital | 2.66% |
Source: Nexqual, July 25, 2026 at 01:44 UTC.
From Baxter International Inc's Latest SEC 10-K Filing (filed 2026-02-12)
Key Strengths & Strategy (as disclosed to the SEC)
- Baxter International Inc., through its subsidiaries, provides a portfolio of healthcare products in the United States.
- The company operates through three segments: Medical Products & Therapies, Healthcare Systems & Technologies, and Pharmaceuticals.
- It offers sterile intravenous (IV) solutions; infusion systems and devices; parenteral nutrition therapies; inhaled anesthetics; generic injectable pharmaceuticals; surgical hemostat and sealant products; advanced surgical equipment; smart bed systems; patient monitoring and diagnostic technologies; and respiratory health devices, as well as advanced equipment for the surgical space comprising operating room integration technologies, precision positioning devices, and other accessories.
- The company also provides specialty injectable pharmaceuticals, inhaled anesthetics, and drug compounding services.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| BDX | Becton, Dickinson and Company | USD 156.36 | ▲ 2.09% |
| EW | Edwards Lifesciences Corporatio | USD 82.63 | ▼ 2.06% |
| CAH | Cardinal Health, Inc. | USD 228.03 | ▲ 3.4% |
| BSX | Boston Scientific Corporation | USD 44.25 | ▲ 2.98% |
| SYK | Stryker Corporation | USD 330.25 | ▲ 6.79% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: July 25, 2026 at 01:44 UTC. This page is informational and not investment advice.